Skip to main content
Erschienen in: Journal of Bone and Mineral Metabolism 1/2012

01.01.2012 | Original Article

FGF23 analysis of a Chinese family with autosomal dominant hypophosphatemic rickets

verfasst von: Yue Sun, Ou Wang, Weibo Xia, Yan Jiang, Mei Li, Xiaoping Xing, Yingying Hu, Huaicheng Liu, Xunwu Meng, Xueying Zhou

Erschienen in: Journal of Bone and Mineral Metabolism | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Autosomal dominant hypophosphatemic rickets (ADHR; MIM 193100) is a hereditary disorder characterized by isolated renal phosphate wasting, hypophosphatemia, and inappropriately normal 1,25-dihydroxyvitamin D3 levels. Recent studies have shown that the fibroblast growth factor 23 (FGF23) gene is responsible for this disease. FGF23 protein is a phosphaturic factor that is elevated in several diseases associated with hypophosphatemia and rickets but varies with disease status in ADHR. In the present study we observed a Chinese family of Han ethnic origin diagnosed with ADHR. The proband is a 30-year-old woman with no history of rickets but with multiple tooth abscesses as a young adult. She presented with progressive painful swelling of the left ankle after a blunt trauma at 26 years of age. She developed back pain, generalized weakness, and fatigue, and she could barely walk at age 27. She was found to have severe hypophosphatemia, low ratio of phosphorus tubule maximum (TmP) to glomerular filtration rate (GFR) (TmP/GFR), and elevated alkaline phosphatase at age 28. Her brother, 26 years old, presented with fatigue at 24 years of age and is normophosphatemic. The parents of this family had no history of rickets or hypophosphatemia. Direct sequence analysis of genomic DNA demonstrated a single heterozygous c.527G>A (p.R176Q) mutation in the FGF23 gene in three family members, including the proband, her brother, and their mother. Intact FGF23 assay of seven time points during the oral phosphate loading test showed no significant relationship between intact FGF23 and serum phosphorus levels of the subject with ADHR and a control. It is probably the first report of a Chinese family with ADHR.
Literatur
1.
Zurück zum Zitat Econs MJ, McEnery PT (1997) Autosomal dominant hypophosphatemic rickets/osteomalacia: clinical characterization of a novel renal phosphate-wasting disorder. J Clin Endocr Metab 82:674–681PubMedCrossRef Econs MJ, McEnery PT (1997) Autosomal dominant hypophosphatemic rickets/osteomalacia: clinical characterization of a novel renal phosphate-wasting disorder. J Clin Endocr Metab 82:674–681PubMedCrossRef
2.
Zurück zum Zitat Bianchine JW, Stambler AA, Harrison HE (1971) Familial hypophosphatemic rickets showing autosomal dominant inheritance. Birth Defects Orig Artic Ser VII:287–294 Bianchine JW, Stambler AA, Harrison HE (1971) Familial hypophosphatemic rickets showing autosomal dominant inheritance. Birth Defects Orig Artic Ser VII:287–294
3.
Zurück zum Zitat Imel EAHS, Econs MJ (2007) FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets. J Bone Miner Res 22:520–526PubMedCrossRef Imel EAHS, Econs MJ (2007) FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets. J Bone Miner Res 22:520–526PubMedCrossRef
4.
Zurück zum Zitat Negri AL, Negrotti T, Alonso G, Pasqualini T (2004) Different forms of clinical presentation of an autosomal dominant hypophosphatemic rickets caused by a FGF23 mutation in one family. Medicina (B Aires) 64:103–106 Negri AL, Negrotti T, Alonso G, Pasqualini T (2004) Different forms of clinical presentation of an autosomal dominant hypophosphatemic rickets caused by a FGF23 mutation in one family. Medicina (B Aires) 64:103–106
5.
Zurück zum Zitat Consortium ADHR (2000) Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 26:345–348CrossRef Consortium ADHR (2000) Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 26:345–348CrossRef
6.
Zurück zum Zitat White KE, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom TM, Econs MJ (2001) Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 60:2079–2086PubMedCrossRef White KE, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom TM, Econs MJ (2001) Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 60:2079–2086PubMedCrossRef
7.
Zurück zum Zitat Bai XY, Miao D, Goltzman D, Karaplis AC (2003) The autosomal dominant hypophosphatemic rickets r176q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency. J Biol Chem 278:9843–9849PubMedCrossRef Bai XY, Miao D, Goltzman D, Karaplis AC (2003) The autosomal dominant hypophosphatemic rickets r176q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency. J Biol Chem 278:9843–9849PubMedCrossRef
8.
Zurück zum Zitat Kiela PR, Ghishan FK (2009) Recent advances in the renal–skeletal–gut axis that controls phosphate homeostasis. Lab Invest 89:7–14PubMedCrossRef Kiela PR, Ghishan FK (2009) Recent advances in the renal–skeletal–gut axis that controls phosphate homeostasis. Lab Invest 89:7–14PubMedCrossRef
9.
Zurück zum Zitat Tiosano D, Hochberg Z (2009) Hypophosphatemia: the common denominator of all rickets. J Bone Miner Metab 27:392–401PubMedCrossRef Tiosano D, Hochberg Z (2009) Hypophosphatemia: the common denominator of all rickets. J Bone Miner Metab 27:392–401PubMedCrossRef
10.
Zurück zum Zitat Weber TJ, Liu S, Indridason OS, Quarles LD (2003) Serum FGF23 levels in normal and disordered phosphorus homeostasis. J Bone Miner Res 18:1227–1234PubMedCrossRef Weber TJ, Liu S, Indridason OS, Quarles LD (2003) Serum FGF23 levels in normal and disordered phosphorus homeostasis. J Bone Miner Res 18:1227–1234PubMedCrossRef
11.
Zurück zum Zitat Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljunggren O, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J, Jüppner H (2003) Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 348:1656–1663PubMedCrossRef Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljunggren O, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J, Jüppner H (2003) Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 348:1656–1663PubMedCrossRef
12.
Zurück zum Zitat Bijvoet OL, Morgan DB, Fourman P (1969) The assessment of phosphate reabsorption. Clin Chim Acta 26:15–24PubMedCrossRef Bijvoet OL, Morgan DB, Fourman P (1969) The assessment of phosphate reabsorption. Clin Chim Acta 26:15–24PubMedCrossRef
13.
Zurück zum Zitat Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, Takeuchi Y, Fujita T, Nakahara K, Yamashita T, Fukumoto S (2002) Increased circulatory level of biologically active full-length Fgf-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 87:4957–4960PubMedCrossRef Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, Takeuchi Y, Fujita T, Nakahara K, Yamashita T, Fukumoto S (2002) Increased circulatory level of biologically active full-length Fgf-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 87:4957–4960PubMedCrossRef
14.
Zurück zum Zitat Imel EA, Peacock M, Pitukcheewanont P, Heller HJ, Ward LM, Shulman D, Kassem M, Rackoff P, Zimering M, Dalkin A, Drobny E, Colussi G, Shaker JL, Hoogendoorn EH, Hui SL, Econs MJ (2006) Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia. J Clin Endocrinol Metab 91:2055–2061PubMedCrossRef Imel EA, Peacock M, Pitukcheewanont P, Heller HJ, Ward LM, Shulman D, Kassem M, Rackoff P, Zimering M, Dalkin A, Drobny E, Colussi G, Shaker JL, Hoogendoorn EH, Hui SL, Econs MJ (2006) Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia. J Clin Endocrinol Metab 91:2055–2061PubMedCrossRef
15.
Zurück zum Zitat Xia W, Meng X, Jiang Y, Li M, Xing X, Pang L, Wang O, Pei Y, Yu LY, Sun Y, Hu Y, Zhou X (2007) Three novel mutations of the PHEX gene in three Chinese families with X-linked dominant hypophosphatemic rickets. Calcif Tissue Int 81:415–420PubMedCrossRef Xia W, Meng X, Jiang Y, Li M, Xing X, Pang L, Wang O, Pei Y, Yu LY, Sun Y, Hu Y, Zhou X (2007) Three novel mutations of the PHEX gene in three Chinese families with X-linked dominant hypophosphatemic rickets. Calcif Tissue Int 81:415–420PubMedCrossRef
16.
Zurück zum Zitat Gribaa M, Younes M, Bouyacoub Y, Korbaa W, Ben Charfeddine I, Touzi M, Adala L, Mamay O, Bergaoui N, Saad A (2009) An autosomal dominant hypophosphatemic rickets phenotype in a Tunisian family caused by a new FGF23 missense mutation. J Bone Miner Metab 28:111–115. doi:10.1007/s00774-009-0111-5 PubMedCrossRef Gribaa M, Younes M, Bouyacoub Y, Korbaa W, Ben Charfeddine I, Touzi M, Adala L, Mamay O, Bergaoui N, Saad A (2009) An autosomal dominant hypophosphatemic rickets phenotype in a Tunisian family caused by a new FGF23 missense mutation. J Bone Miner Metab 28:111–115. doi:10.​1007/​s00774-009-0111-5 PubMedCrossRef
17.
Zurück zum Zitat Wilson DR, York SE, Jaworski ZF, Yendt ER (1965) Studies in hypophosphatemic vitamin D-refractory osteomalacia in adults: oral phosphate supplements as an adjunct to therapy. Medicine (Baltim) 44:99–134 Wilson DR, York SE, Jaworski ZF, Yendt ER (1965) Studies in hypophosphatemic vitamin D-refractory osteomalacia in adults: oral phosphate supplements as an adjunct to therapy. Medicine (Baltim) 44:99–134
18.
Zurück zum Zitat Harrison HE, Harrison HC, Lifshitz F, Johnson AD (1966) Growth disturbance in hereditary hypophosphatemia. Am J Dis Child 112:290–297PubMed Harrison HE, Harrison HC, Lifshitz F, Johnson AD (1966) Growth disturbance in hereditary hypophosphatemia. Am J Dis Child 112:290–297PubMed
19.
20.
Zurück zum Zitat Kruse K, Woelfel D, Storm TM (2001) Loss of renal phosphate wasting in a child with autosomal dominant hypophosphatemic rickets caused by a FGF23 mutation. Horm Res 55:305–308PubMedCrossRef Kruse K, Woelfel D, Storm TM (2001) Loss of renal phosphate wasting in a child with autosomal dominant hypophosphatemic rickets caused by a FGF23 mutation. Horm Res 55:305–308PubMedCrossRef
21.
Zurück zum Zitat Yamashita T (2005) Structural and biochemical properties of fibroblast growth factor 23. Ther Apher Dial 9:313–318PubMedCrossRef Yamashita T (2005) Structural and biochemical properties of fibroblast growth factor 23. Ther Apher Dial 9:313–318PubMedCrossRef
22.
Zurück zum Zitat Mirams M, Robinson BG, Mason RS, Nelson AE (2004) Bone as a source of FGF23: regulation by phosphate? Bone (NY) 35:1192–1199CrossRef Mirams M, Robinson BG, Mason RS, Nelson AE (2004) Bone as a source of FGF23: regulation by phosphate? Bone (NY) 35:1192–1199CrossRef
23.
Zurück zum Zitat Liu S, Gupta A, Quarles LD (2007) Emerging role of fibroblast growth factor 23 in a bone-kidney axis regulating systemic phosphate homeostasis and extracellular matrix mineralization. Curr Opin Nephrol Hypertens 16:329–335PubMedCrossRef Liu S, Gupta A, Quarles LD (2007) Emerging role of fibroblast growth factor 23 in a bone-kidney axis regulating systemic phosphate homeostasis and extracellular matrix mineralization. Curr Opin Nephrol Hypertens 16:329–335PubMedCrossRef
24.
Zurück zum Zitat Endo I, Fukumoto S, Ozono K, Namba N, Tanaka H, Inoue D, Minagawa M, Sugimoto T, Yamauchi M, Michigami T, Matsumoto T (2008) Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients. Proposal of diagnostic criteria using FGF23 measurement. Bone (NY) 42:1235–1239CrossRef Endo I, Fukumoto S, Ozono K, Namba N, Tanaka H, Inoue D, Minagawa M, Sugimoto T, Yamauchi M, Michigami T, Matsumoto T (2008) Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients. Proposal of diagnostic criteria using FGF23 measurement. Bone (NY) 42:1235–1239CrossRef
25.
Zurück zum Zitat Laroche M, Boyer JF, Jahafar H, Allard J, Tack I (2009) Normal FGF23 levels in adult idiopathic phosphate diabetes. Calcif Tissue Int 84:112–117PubMedCrossRef Laroche M, Boyer JF, Jahafar H, Allard J, Tack I (2009) Normal FGF23 levels in adult idiopathic phosphate diabetes. Calcif Tissue Int 84:112–117PubMedCrossRef
26.
Zurück zum Zitat Ito N, Fukumoto S, Takeuchi Y, Takeda S, Suzuki H, Yamashita T, Fujita T (2007) Effect of acute changes of serum phosphate on fibroblast growth factor (FGF)23 levels in humans. J Bone Miner Metab 25:419–422PubMedCrossRef Ito N, Fukumoto S, Takeuchi Y, Takeda S, Suzuki H, Yamashita T, Fujita T (2007) Effect of acute changes of serum phosphate on fibroblast growth factor (FGF)23 levels in humans. J Bone Miner Metab 25:419–422PubMedCrossRef
Metadaten
Titel
FGF23 analysis of a Chinese family with autosomal dominant hypophosphatemic rickets
verfasst von
Yue Sun
Ou Wang
Weibo Xia
Yan Jiang
Mei Li
Xiaoping Xing
Yingying Hu
Huaicheng Liu
Xunwu Meng
Xueying Zhou
Publikationsdatum
01.01.2012
Verlag
Springer Japan
Erschienen in
Journal of Bone and Mineral Metabolism / Ausgabe 1/2012
Print ISSN: 0914-8779
Elektronische ISSN: 1435-5604
DOI
https://doi.org/10.1007/s00774-011-0285-5

Weitere Artikel der Ausgabe 1/2012

Journal of Bone and Mineral Metabolism 1/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.